Results 151 to 160 of about 4,025 (198)
Synthesis and Biological Evaluation of Iodinated Fidaxomicin Antibiotics [PDF]
Helvetica Chimica Acta, 2020 Fidaxomicin (1, tiacumicin B, lipiarmycin A3) is a marketed antibiotic that is used in the treatment of C. difficile infections. Based on the analysis of a cryo- EM structure of fidaxomicin binding to its target enzyme (RNA-polymerase), a cation-p ...
Inga S Shchelik +2 more
exaly +5 more sources
Some of the next articles are maybe not open access.
Related searches:
Related searches:
Fidaxomicin: first-in-class macrocyclic antibiotic
Expert Review of Anti-Infective Therapy, 2011The incidence of Clostridium difficile has doubled over the past 15 years, and rising mortality rates associated with this infection have followed in its wake. C. difficile infection (CDI) has supplanted methicillin-resistant Staphylococcus aureus as the major cause of nosocomial infection.
Kathleen Mullane, Sherwood Gorbach
exaly +3 more sources
Phenolic Substitution in Fidaxomicin: A Semisynthetic Approach to Antibiotic Activity Across Species** [PDF]
ChemBioChem, 2023 Fidaxomicin (Fdx) is a natural product antibiotic with potent activity against Clostridioides difficile and other Gram-positive bacteria such as Mycobacterium tuberculosis.
Yves Mattenberger +2 more
exaly +2 more sources
Chemistry and Biology of the Clinically Used Macrolactone Antibiotic Fidaxomicin [PDF]
Helvetica Chimica Acta, 2020 Fidaxomicin (1, lipiarmycin A3, clostomicin B1, tiacumicin B) constitutes a glycosylated 18-membered macrolactone and is a natural product isolated from various soil bacteria.
Karl Gademann
exaly +2 more sources
Effect of using fidaxomicin on recurrent Clostridium difficile infection [PDF]
Journal of Hospital Infection, 2019 Fidaxomicin is a macrocyclic antibiotic licensed for treating Clostridium difficile infection (CDI). In the UK, fidaxomicin is often reserved for severe CDI or recurrences.
Tariq Iqbal, E Holden, M I Garvey
exaly +2 more sources
Drugs, 2011
Fidaxomicin is a first-in-class macrocyclic antibacterial that primarily demonstrates activity against species of clostridia, predominantly Clostridium difficile, while having limited or no activity against normal faecal microflora. Fidaxomicin is minimally absorbed following oral administration and is excreted almost solely in the faeces.
J. Cada Dennis +2 more
openaire +3 more sources
Fidaxomicin is a first-in-class macrocyclic antibacterial that primarily demonstrates activity against species of clostridia, predominantly Clostridium difficile, while having limited or no activity against normal faecal microflora. Fidaxomicin is minimally absorbed following oral administration and is excreted almost solely in the faeces.
J. Cada Dennis +2 more
openaire +3 more sources
Cost-Effectiveness Analysis Evaluating Fidaxomicin versus Oral Vancomycin for the Treatment of Clostridium difficile Infection in the United States [PDF]
Value in Health, 2013 ObjectivesFidaxomicin is a novel treatment for Clostridium difficile infections (CDIs). This new treatment, however, is associated with a higher acquisition cost compared with alternatives.
David Hutton, Paul Stranges
exaly +2 more sources